Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR antibody-drug conjugate CPO301

An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal antibody moiety binds to EGFR on tumor cell surfaces. Upon binding and internalization, the cytotoxic agent is released and kills the EGFR-expressing cancer cells, through an as of yet unknown mechanism of action. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-EGFR ADC CPO301
anti-EGFR antibody-drug conjugate SYS6010
Code name:CPO 301
CPO-301
CPO301
SYS 6010
SYS-6010
SYS6010
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search